10-K: BioRestorative Therapies Grants Stock Options to Executive and Board Member

BioRestorative Therapies has granted stock options to an executive and a board member as part of their compensation packages.

Summary

• BioRestorative Therapies granted stock options to Nickolay Kukekov, an executive, and Lance Alstodt, the President and CEO, on February 13, 2024.
• The options for both individuals have an exercise price of $1.45 per share.
• Nickolay Kukekov received options for 79,646 shares, which vest monthly over 12 months.
• Lance Alstodt received options for 438,596 shares, with 50% vesting immediately and the remainder vesting quarterly over two years.
• Both options expire on February 13, 2034.
• The options are subject to the terms of the BioRestorative Therapies, Inc. 2021 Stock Incentive Plan.
• The document outlines the terms of exercise, vesting, and what happens upon termination of service, death, or disability.
• The document also includes details on change of control scenarios and tax liabilities.

Sentiment

Score: 7

Explanation: The document is a standard stock option agreement, which is generally positive for the recipients and indicates the company is using common methods to incentivize key personnel. The sentiment is neutral to slightly positive.

Positives

• The options provide an incentive for the executive and board member to contribute to the company's success.
• The vesting schedule encourages long-term commitment.
• The change of control clause provides some protection for the option holders in the event of a company sale.

Negatives

• The options are subject to forfeiture if the individual's service is terminated for cause.
• The options are not transferable except by will or the laws of descent and distribution.

Risks

• The value of the options is dependent on the future performance of the company's stock.
• The options may become worthless if the company's stock price does not increase above the exercise price.
• The company makes no guarantees regarding the tax treatment of the options.

Future Outlook

The document does not contain any specific forward-looking statements about the company's future performance, but the stock options are intended to incentivize the recipients to contribute to the company's success.

Management Comments

• The grant of the Option is made in consideration of the services to be rendered by the Participant to the Company.
• The Company does not commit to structure the Option to reduce or eliminate the Participants liability for Tax-Related Items.

Industry Context

Stock options are a common form of compensation for executives and board members in the biotechnology industry, aligning their interests with those of the shareholders.

Comparison to Industry Standards

• The vesting schedules and terms of the options are generally consistent with industry standards for executive compensation.
• The use of both time-based and performance-based vesting is a common practice.
• The change of control provisions are also typical in such agreements.

Stakeholder Impact

• Shareholders may benefit from the increased motivation of key personnel.
• Employees may be motivated by the potential for stock ownership.
• The company may benefit from the long-term commitment of the option holders.

Next Steps

• The options will vest according to the specified schedules.
• The recipients may exercise their options at any time after vesting and before the expiration date.
• The company will need to track the vesting and exercise of the options for accounting and tax purposes.

Key Dates

Keywords

stock options, incentive stock options, non-qualified stock options, vesting, exercise price, change in control, BioRestorative Therapies, executive compensation, stock incentive plan